ClinicalTrials.gg
RecruitingNCT07091617Updated Nov 4, 2026

Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer

An interventional study of Telemedicine and Genetic Testing in Miscellaneous Neoplasm, Nos and Non-Neoplastic Condition, Nos, sponsored by Alliance for Clinical Trials in Oncology. Recruiting at 327 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Alliance for Clinical Trials in Oncology · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 4, 2026Site recruiting status changed15 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
535
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This phase III trial compares the use of a digital chatbot enabled intervention to standard remote genetic services for increasing uptake of genetic counseling and testing among adolescents and young adult (AYA) cancer patients. Genetic testing for cancer predisposition syndromes has become standard evidence-based practice and can inform enhanced screening and risk reducing measures to reduce cancer morbidity and mortality. Despite this, many AYAs are not receiving recommended genetic counseling and testing. Offering remote telehealth services can address access barriers and chatbots and texting interventions could enhance patient outcomes and reduce provider and staff time. The use of a digital chatbot enabled intervention may be equally as effective as standard remote genetic services in AYA cancer patients undergoing genetic testing.

Read the detailed description

The primary and secondary objectives of the study:

PRIMARY OBJECTIVES:

I. To evaluate the efficacy of an enhanced eHealth and chatbot enabled delivery model to increase uptake of genetic counseling.

II. To evaluate the efficacy of an enhanced eHealth and chatbot enabled delivery model to increase uptake of genetic testing.

SECONDARY OBJECTIVE:

I. To evaluate the efficacy of an enhanced eHealth and chatbot enabled delivery model to provide non-inferior short-term and longitudinal cognitive (e.g. knowledge), affective (e.g. distress), and behavioral outcomes (e.g. cancer screening and communication to relatives) and costs.

EXPLORATORY OBJECTIVES:

I. To test for moderators of uptake of counseling and testing (primary objectives).

II. To test for moderators of short-term and longitudinal patient outcomes (secondary objectives).

III. To identify facilitators and barriers to implementation of the enhanced eHealth and chatbot enabled delivery model and standard remote services.

OUTLINE: Patients are randomized to 1 of 2 arms. Non-patient participants are assigned to arm 3.

ARM I: Patients attend a standard of care telehealth visit with a genetic counselor for pretest genetic education. Patients then undergo standard of care genetic testing and attend a telehealth visit with a genetic counselor for disclosure of results.

ARM II: Patients receive access to the Genetic Journey Chatbot and choose to complete digital pre-test genetic education via the digital tool or via telehealth visit with a genetic counselor. Via the chatbot, patients may request a telehealth visit with a genetic counselor at any time to answer unresolved questions. Patients then undergo standard of care genetic testing and attend a telehealth visit with a genetic counselor for disclosure of results. The chatbot remains available to answer questions, assess barriers, and provide reminders for next steps during the testing period.

ARM III: Non-patient participants complete an interview on study.

After completion of study intervention, patients are followed up at 6 and 12 months.

02

Conditions studied

  • Miscellaneous Neoplasm, Nos
  • Non-Neoplastic Condition, Nos
03

In context

Lead sponsor

Alliance for Clinical Trials in Oncology is the lead sponsor of 509 studies on the registry; 28 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  • PATIENTS: Age ≥ 18 years and ≤ 39 years at the time of enrollment
  • PATIENTS: AYA cancer patients and survivors. This includes patients at any stage of diagnosis (e.g., newly diagnosed, in treatment, in survivorship) and a cancer diagnosis (including pediatric cancers) at any age ≤ 39 years old. Given targeted therapies for BRCA+ and microsatellite instability (MSI)-high/Lynch Syndrome patients and benefit to relatives, patients with cancer are included. Any history of cancer, regardless of being in treatment or not
  • PATIENTS: Language: In order to complete the mandatory patient-completed measures and receive genetic education and counseling, participants must be able to speak and read English or Spanish
  • PATIENTS: No known diagnosis of dementia or cognitive impairment. Persons with impaired decision-making capacity are ineligible as they need to be able to understand genetic test results, its implications for the patient and family, and explain genetic test results to their family members
  • PATIENTS: No persons with a known psychiatric or documented developmental disorder that affects cognitive or emotional functions to the extent that the capacity for judgment and reason is significantly diminished, such that they cannot participate based on the judgment of the treating physician
  • PATIENTS: Participants must meet National Comprehensive Cancer Network (NCCN) guidelines for genetic testing assessment provided by Penn Telegenetics by the Eligibility Verification Assessment (EVA) chatbot, or paper forms and genetic counselor's review
  • NON-PATIENT PARTICIPANT: Non-patient participants eligible for this study include: oncology providers, members of the care team and clinic staff, genetic counselors, and insurers (i.e., people who work in financial services and/or for insurance companies) who participate in oncology care among AYA in community for this study
  • NON-PATIENT PARTICIPANT: Age ≥ 18 years
  • NON-PATIENT PARTICIPANT: Non-patient participants must be able to speak and read English or Spanish in order to participate in the key informant interviews
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
535 participants (estimated)

Study arms

  • Active comparator
    Arm I (standard remote genetic services)

    Patients attend a standard of care telehealth visit with a genetic counselor for pretest genetic education. Patients then undergo standard of care genetic testing and attend a telehealth visit with a genetic counselor for disclosure of results.

    Other: Telemedicine · Other: Genetic Testing · Other: Survey Administration

  • Experimental
    Arm II (Genetic Journey Chatbot)

    Patients receive access to the Genetic Journey Chatbot and choose to complete digital pre-test genetic education via the digital tool or via telehealth visit with a genetic counselor. Via the chatbot, patients may request a telehealth visit with a genetic counselor at any time to answer unresolved questions. Patients then undergo standard of care genetic testing and attend a telehealth visit with a genetic counselor for disclosure of results. The chatbot remains available to answer questions, assess barriers, and provide reminders for next steps during the testing period.

    Other: Telemedicine · Other: Genetic Testing · Other: Internet-Based Intervention · Other: Educational Intervention · Behavioral: Patient Navigation · Other: Interview · Other: Survey Administration

Interventions

  • OtherTelemedicine

    Undergo telehealth visit with genetic counselor for pretest genetic education

  • OtherGenetic Testing

    Complete standard of care genetic testing

  • OtherTelemedicine

    Undergo telehealth visit with genetic counselor for disclosure of results

  • OtherInternet-Based Intervention

    Receive access to Genetic Journey Chatbot

  • OtherEducational Intervention

    Complete digital pre-test genetic education

  • BehavioralPatient Navigation

    Utilize chatbot to answer questions, assess barriers, and provide reminders for next steps during the testing period

  • OtherInterview

    Complete interview

  • OtherSurvey Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Uptake of genetic counseling

    Defined as a binary outcome of whether an adolescent or young adult (AYA) underwent genetic counseling within 6 months post completion of the baseline survey. Will be compared between randomized arms using Cochran-Mantel-Haenszel (CMH) tests stratified by gender and a Bonferroni correction will be applied to control family-wise type I error.

    Time frame: Within 6 months of baseline

  2. Uptake of genetic testing

    Defined as a binary outcome of whether an AYA underwent genetic testing within 6 months post completion of the baseline survey. Will be compared between randomized arms using CMH tests stratified by gender and a Bonferroni correction will be applied to control family-wise type I error.

    Time frame: Within 6 months of baseline

Secondary outcomes

  1. Knowledge of genetic disease

    Obtained from the KnowGene scale. Will be compared using non-inferiority testing with the equivalent of a 0.3 standard deviation (SD) non-inferiority margin. The lower limit of the one-sided 97.5% confidence limit for the difference in means will be compared with the non-inferiority margin and non-inferiority will be concluded if the interval fully lies above -0.3 SD. Longitudinal analyses will include model based analysis using generalized linear models of endpoints over time with link function determined by distribution of the endpoint being modeled and adjusting for baseline patient and disease characteristics.

    Time frame: Up to 42 months post registration

  2. Test result recall

    Measured via the Test Result Recall scale. Will be compared using non-inferiority testing with the equivalent of a 0.3 SD non-inferiority margin. The lower limit of the one-sided 97.5% confidence limit for each secondary endpoint at T2 (the primary time point of interest for the secondary analyses) will be compared with the non-inferiority margin and non-inferiority will be concluded if the interval fully lies above -0.3 SD. Longitudinal analyses will include model based analysis using generalized linear models of endpoints over time with link function determined by distribution of the endpoint being modeled and adjusting for baseline patient and disease characteristics.

    Time frame: Up to 42 months post registration

  3. Perceptions of genetic disease

    Measured via the Perceived Risk scale. Will be compared using non-inferiority testing with the equivalent of a 0.3 SD non-inferiority margin. The lower limit of the one-sided 97.5% confidence limit for the difference in means will be compared with the non-inferiority margin and non-inferiority will be concluded if the interval fully lies above -0.3 SD. Longitudinal analyses will include model based analysis using generalized linear models of endpoints over time with link function determined by distribution of the endpoint being modeled and adjusting for baseline patient and disease characteristics.

    Time frame: Up to 42 months post registration

  4. Anxiety

    Measured via Patient Reported Outcome Measurement Information System (PROMIS) anxiety score. Will be compared using non-inferiority testing with the equivalent of a 0.3 SD non-inferiority margin. The lower limit of the one-sided 97.5% confidence limit for the difference in means will be compared with the non-inferiority margin and non-inferiority will be concluded if the interval fully lies above -0.3 SD. Longitudinal analyses will include model based analysis using generalized linear models of endpoints over time with link function determined by distribution of the endpoint being modeled and adjusting for baseline patient and disease characteristics.

    Time frame: Up to 42 months post registration

  5. Depression

    Measured via PROMIS Depression score. Will be compared using non-inferiority testing with the equivalent of a 0.3 SD non-inferiority margin. The lower limit of the one-sided 97.5% confidence limit for the difference in means will be compared with the non-inferiority margin and non-inferiority will be concluded if the interval fully lies above -0.3 SD. Longitudinal analyses will include model based analysis using generalized linear models of endpoints over time with link function determined by distribution of the endpoint being modeled and adjusting for baseline patient and disease characteristics.

    Time frame: Up to 42 months post registration

  6. Disease-specific distress

    Measured via the Revised Impact of Events Scale score. Will be compared using non-inferiority testing with the equivalent of a 0.3 SD non-inferiority margin. The lower limit of the one-sided 97.5% confidence limit for the difference in means will be compared with the non-inferiority margin and non-inferiority will be concluded if the interval fully lies above -0.3 SD. Longitudinal analyses will include model based analysis using generalized linear models of endpoints over time with link function determined by distribution of the endpoint being modeled and adjusting for baseline patient and disease characteristics.

    Time frame: Up to 42 months post registration

  7. Impact of cancer risk

    Measured via the Multi-dimensional Impact of Cancer Risk Assessment score. Will be compared using non-inferiority testing with the equivalent of a 0.3 SD non-inferiority margin. The lower limit of the one-sided 97.5% confidence limit or each secondary endpoint at T2 (the primary time point of interest for the secondary analyses) will be compared with the non-inferiority margin and non-inferiority will be concluded if the interval fully lies above -0.3 SD. Longitudinal analyses will include model based analysis using generalized linear models of endpoints over time with link function determined by distribution of the endpoint being modeled and adjusting for baseline patient and disease characteristics

    Time frame: Up to 42 months post registration

  8. Satisfaction with genetic services

    Measured via the Satisfaction with Genetic Services scale. Will be compared using non-inferiority testing with the equivalent of a 0.3 SD non-inferiority margin. The lower limit of the one-sided 97.5% confidence limit or each secondary endpoint at T2 (the primary time point of interest for the secondary analyses) will be compared with the non-inferiority margin and non-inferiority will be concluded if the interval fully lies above -0.3 SD.

    Time frame: Up to 30 months post registration

  9. Attitude toward genetic testing

    Measured via Attitudes Toward Genetic Testing scale. Will be compared using non-inferiority testing with the equivalent of a 0.3 SD non-inferiority margin. The lower limit of the one-sided 97.5% confidence limit or each secondary endpoint at T2 (the primary time point of interest for the secondary analyses) will be compared with the non-inferiority margin and non-inferiority will be concluded if the interval fully lies above -0.3 SD.

    Time frame: Up to 24 months post registration

  10. Lifestyle behaviors

    Will be compared using non-inferiority testing with the equivalent of a 0.3 SD non-inferiority margin. The lower limit of the one-sided 97.5% confidence limit for the difference in means will be compared with the non-inferiority margin and non-inferiority will be concluded if the interval fully lies above -0.3 SD. Longitudinal analyses will include model based analysis using generalized linear models of endpoints over time with link function determined by distribution of the endpoint being modeled and adjusting for baseline patient and disease characteristics.

    Time frame: Up to 42 months post registration

  11. Health behaviors

    Measured via the Screening Health behaviors score. Will be compared using non-inferiority testing with the equivalent of a 0.3 SD non-inferiority margin. The lower limit of the one-sided 97.5% confidence limit for the difference in means will be compared with the non-inferiority margin and non-inferiority will be concluded if the interval fully lies above -0.3 SD. Longitudinal analyses will include model based analysis using generalized linear models of endpoints over time with link function determined by distribution of the endpoint being modeled and adjusting for baseline patient and disease characteristics.

    Time frame: Up to 42 months post registration

  12. Communication to at-risk relatives

    Will be compared using non-inferiority testing with the equivalent of a 0.3 SD non-inferiority margin. The lower limit of the one-sided 97.5% confidence limit for the difference in means will be compared with the non-inferiority margin and non-inferiority will be concluded if the interval fully lies above -0.3 SD. Longitudinal analyses will include model based analysis using generalized linear models of endpoints over time with link function determined by distribution of the endpoint being modeled and adjusting for baseline patient and disease characteristics.

    Time frame: Up to 42 months post registration

  13. Genetic counselor time

    o Will be compared using non-inferiority testing with the equivalent of a 0.3 SD non-inferiority margin. The lower limit of the one-sided 97.5% confidence limit for the difference in means will be compared with the non-inferiority margin and non-inferiority will be concluded if the interval fully lies above -0.3 SD. Longitudinal analyses will include model based analysis using generalized linear models of endpoints over time with link function determined by distribution of the endpoint being modeled and adjusting for baseline patient and disease characteristics.

    Time frame: Up to 24 months post registration

  14. Testing costs

    Measured by 2 patient reported items

    Time frame: Up to 36 months post registration

  15. Costs of the intervention

    o Will be estimated from a societal perspective, including direct medical and nonmedical costs. These include intervention and chatbot hosting, telecommunication services, personnel and patient time. Information to estimate intervention costs collected from study billing and payment records (e.g. website hosting, chatbot usage and time, videoconferencing and phone usage) and telegenetic staff logs (personnel time). The cost of personnel time will be based on institution-specific salaries, including fringe benefits. In sensitivity analysis, will substitute site-specific salary information with national average wage rates for the relevant occupational categories. Information about other out-of-pocket costs for testing (e.g. copayments) will be obtained through participant surveys. Patient time costs will be valued using national average wage rates for participant-specified occupations.

    Time frame: Up to 42 months post registration

07

Study locations

323 of 327 sites recruiting

Showing the first 100 of 327 sites. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Apr 2028, 28 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 29, 2025
StartActual
Dec 10, 2025
Primary completionEst.
Apr 28, 2028
CompletionEst.
Apr 30, 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
15 sites added, 1 site removed. 3 sites changed recruiting status (2 now suspended, 1 now recruiting)
Show 3 sites
  • Greater Regional Medical Center · Creston, United StatesRecruiting→Suspended
  • Novant Health New Hanover Regional Medical Center · Wilmington, United StatesSuspended→Recruiting
  • Bay Area Hospital · Coos Bay, United StatesRecruiting→Suspended
Show 15 added (15 United States)
  • Harold Alfond Center for Cancer Care · Augusta, United States
  • MaineHealth Waldo Hospital · Belfast, United States
  • MaineHealth Cancer Care and IV Therapy - Brunswick · Brunswick, United States
  • MaineHealth LincolnHealth Hospital · Damariscotta, United States
  • MaineHealth Stephens Hospital · Norway, United States
  • Penobscot Bay Medical Center · Rockport, United States
  • MaineHealth Cancer Care and IV Therapy - Sanford · Sanford, United States
  • Maine Children's Cancer Program · Scarborough, United States
  • MaineHealth Maine Medical Center- Scarborough · Scarborough, United States
  • MaineHealth Cancer Care and IV Therapy - South Portland · South Portland, United States
  • Trinity Health IHA Medical Group - Primary Care - Clarkston · Clarkston, United States
  • Dominican Santa Cruz Hospital · Santa Cruz, United States
  • Stockton Hematology Oncology Medical Group · Stockton, United States
  • Trinity Health IHA Medical Group-Alice Gustafson Center · Pontiac, United States
  • Providence Swedish Cancer Institute · Everett, United States
Show 1 removed
  • Newland Medical Associates-Pontiac · Pontiac, United States
across 2 updates, Oct 2, 2026 – Nov 4, 2026
Site contacts
Changed at 41 sites. See the sites
Show 41 sites
  • Greater Regional Medical Center · Creston, United StatesContact removed •••3305Contact removed (no phone or email listed)
  • Novant Health New Hanover Regional Medical Center · Wilmington, United StatesContact added •••3000Contact added (no phone or email listed)
  • Bay Area Hospital · Coos Bay, United StatesContact removed c•••@bayareahospital.org · •••8392Contact removed (no phone or email listed)
  • Cancer Center at Saint Joseph's · Phoenix, United StatesContact person changed (no phone or email listed)
  • Mission Hope Medical Oncology - Arroyo Grande · Arroyo Grande, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center - Carmichael · Carmichael, United StatesContact person changed (no phone or email listed)
  • Mercy San Juan Medical Center · Carmichael, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center - Elk Grove · Elk Grove, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center · Merced, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center - Rocklin · Rocklin, United StatesContact person changed (no phone or email listed)
  • Mercy Cancer Center - Sacramento · Sacramento, United StatesContact person changed (no phone or email listed)
  • Pacific Central Coast Health Center-San Luis Obispo · San Luis Obispo, United StatesContact person changed (no phone or email listed)
  • Mission Hope Medical Oncology - Santa Maria · Santa Maria, United StatesContact person changed (no phone or email listed)
  • Saint Joseph's Medical Center · Stockton, United StatesContact person changed (no phone or email listed)
  • Woodland Memorial Hospital · Woodland, United StatesContact person changed (no phone or email listed)
  • Penrose-Saint Francis Healthcare · Colorado Springs, United StatesContact person changed (no phone or email listed)
  • Rocky Mountain Cancer Centers-Penrose · Colorado Springs, United StatesContact person changed (no phone or email listed)
  • Saint Francis Cancer Center · Colorado Springs, United StatesContact person changed (no phone or email listed)
  • CommonSpirit Cancer Center Mercy · Durango, United StatesContact person changed (no phone or email listed)
  • Mercy Medical Center · Durango, United StatesContact person changed (no phone or email listed)
  • CommonSpirit Saint Anthony Hospital Cancer Center · Lakewood, United StatesContact person changed (no phone or email listed)
  • Longmont United Hospital · Longmont, United StatesContact person changed (no phone or email listed)
  • Saint Mary Corwin Medical Center · Pueblo, United StatesContact person changed (no phone or email listed)
  • Saint Anthony North Hospital · Westminster, United StatesContact person changed (no phone or email listed)
  • CommonSpirit Saint Joseph Hospital - Bardstown · Bardstown, United StatesContact person changed (no phone or email listed)
  • Commonwealth Cancer Center-Corbin · Corbin, United StatesContact person changed (no phone or email listed)
  • CommonSpirit Saint Joseph Hospital - Lexington · Lexington, United StatesContact person changed (no phone or email listed)
  • Saint Joseph Radiation Oncology Resource Center · Lexington, United StatesContact person changed (no phone or email listed)
  • CommonSpirit Saint Joseph Medical Center - East Lexington · Lexington, United StatesContact person changed (no phone or email listed)
  • CommonSpirit Saint Joseph Hospital London · London, United StatesContact person changed (no phone or email listed)
  • …and 11 more sites
across 2 updates, Oct 2, 2026 – Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    4 sites added, 1 site removed
    Show 4 added (4 United States)
    • Dominican Santa Cruz Hospital · Santa Cruz, United States
    • Stockton Hematology Oncology Medical Group · Stockton, United States
    • Trinity Health IHA Medical Group-Alice Gustafson Center · Pontiac, United States
    • Providence Swedish Cancer Institute · Everett, United States
    Show 1 removed
    • Newland Medical Associates-Pontiac · Pontiac, United States
    Site contacts Changed at 38 sites. See the sites
    Show 38 sites
    • Cancer Center at Saint Joseph's · Phoenix, United StatesContact person changed (no phone or email listed)
    • Mission Hope Medical Oncology - Arroyo Grande · Arroyo Grande, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Carmichael · Carmichael, United StatesContact person changed (no phone or email listed)
    • Mercy San Juan Medical Center · Carmichael, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Elk Grove · Elk Grove, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center · Merced, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Rocklin · Rocklin, United StatesContact person changed (no phone or email listed)
    • Mercy Cancer Center - Sacramento · Sacramento, United StatesContact person changed (no phone or email listed)
    • Pacific Central Coast Health Center-San Luis Obispo · San Luis Obispo, United StatesContact person changed (no phone or email listed)
    • Mission Hope Medical Oncology - Santa Maria · Santa Maria, United StatesContact person changed (no phone or email listed)
    • Saint Joseph's Medical Center · Stockton, United StatesContact person changed (no phone or email listed)
    • Woodland Memorial Hospital · Woodland, United StatesContact person changed (no phone or email listed)
    • Penrose-Saint Francis Healthcare · Colorado Springs, United StatesContact person changed (no phone or email listed)
    • Rocky Mountain Cancer Centers-Penrose · Colorado Springs, United StatesContact person changed (no phone or email listed)
    • Saint Francis Cancer Center · Colorado Springs, United StatesContact person changed (no phone or email listed)
    • CommonSpirit Cancer Center Mercy · Durango, United StatesContact person changed (no phone or email listed)
    • Mercy Medical Center · Durango, United StatesContact person changed (no phone or email listed)
    • CommonSpirit Saint Anthony Hospital Cancer Center · Lakewood, United StatesContact person changed (no phone or email listed)
    • Longmont United Hospital · Longmont, United StatesContact person changed (no phone or email listed)
    • Saint Mary Corwin Medical Center · Pueblo, United StatesContact person changed (no phone or email listed)
    • Saint Anthony North Hospital · Westminster, United StatesContact person changed (no phone or email listed)
    • CommonSpirit Saint Joseph Hospital - Bardstown · Bardstown, United StatesContact person changed (no phone or email listed)
    • Commonwealth Cancer Center-Corbin · Corbin, United StatesContact person changed (no phone or email listed)
    • CommonSpirit Saint Joseph Hospital - Lexington · Lexington, United StatesContact person changed (no phone or email listed)
    • Saint Joseph Radiation Oncology Resource Center · Lexington, United StatesContact person changed (no phone or email listed)
    • CommonSpirit Saint Joseph Medical Center - East Lexington · Lexington, United StatesContact person changed (no phone or email listed)
    • CommonSpirit Saint Joseph Hospital London · London, United StatesContact person changed (no phone or email listed)
    • CommonSpirit Saint Joseph Hospital Mount Sterling · Mount Sterling, United StatesContact person changed (no phone or email listed)
    • CHI Health Saint Francis · Grand Island, United StatesContact person changed (no phone or email listed)
    • CHI Health Good Samaritan · Kearney, United StatesContact person changed (no phone or email listed)
    • …and 8 more sites
    + 1 other change: verification date
  2. Oct 2, 2026
    11 sites added. 3 sites changed recruiting status (2 now suspended, 1 now recruiting)
    Show 3 sites
    • Greater Regional Medical Center · Creston, United StatesRecruiting→Suspended
    • Novant Health New Hanover Regional Medical Center · Wilmington, United StatesSuspended→Recruiting
    • Bay Area Hospital · Coos Bay, United StatesRecruiting→Suspended
    Show 11 added (11 United States)
    • Harold Alfond Center for Cancer Care · Augusta, United States
    • MaineHealth Waldo Hospital · Belfast, United States
    • MaineHealth Cancer Care and IV Therapy - Brunswick · Brunswick, United States
    • MaineHealth LincolnHealth Hospital · Damariscotta, United States
    • MaineHealth Stephens Hospital · Norway, United States
    • Penobscot Bay Medical Center · Rockport, United States
    • MaineHealth Cancer Care and IV Therapy - Sanford · Sanford, United States
    • Maine Children's Cancer Program · Scarborough, United States
    • MaineHealth Maine Medical Center- Scarborough · Scarborough, United States
    • MaineHealth Cancer Care and IV Therapy - South Portland · South Portland, United States
    • Trinity Health IHA Medical Group - Primary Care - Clarkston · Clarkston, United States
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Greater Regional Medical Center · Creston, United StatesContact removed •••3305Contact removed (no phone or email listed)
    • Novant Health New Hanover Regional Medical Center · Wilmington, United StatesContact added •••3000Contact added (no phone or email listed)
    • Bay Area Hospital · Coos Bay, United StatesContact removed c•••@bayareahospital.org · •••8392Contact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07091617
Responsible party
Sponsor
First posted
Jul 29, 2025
Start date
Dec 10, 2025
Primary completion
Apr 28, 2028 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Rachel Wills
Contact
cancercontrolprotocols@alliancenctn.org
773-702-9171
Angela Bradbury, MD
study chair · Alliance for Clinical Trials in Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion